Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers
November 16, 2023 at 04:05 pm EST
Share
Myriad Genetics, Inc. and Personalis, Inc. announced a non-exclusive collaboration through which Myriad will market the Personalis® ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners who use the MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests. Personalis? ImmunoID NeXT platform is the most discriminating platform to power drug development biomarker efforts and has been utilized by the top 20 global bio-pharma companies.
It provides high-quality exome/transcriptome assays for cancer FFPE samples.
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.